Nyxoah Raises $110 Million to Accelerate US Launch of Genio Sleep Apnea Device

MT Newswires Live

Jun 11

Nyxoah (NYXH) secured $110 million in new capital to support the US commercial rollout of its Genio sleep apnea treatment system, the medical technology company said late Wednesday.

The company completed a $95 million equity financing and expects to receive the second $15 million tranche of its European Investment Bank loan by the end of June.

Nyxoah said the funding will help accelerate the commercialization of Genio in the US, where it has built a sales force of 40 representatives following the device's US Food and Drug Administration approval in 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2642476770"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2642476770\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2642476770?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-11 04:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642476770","market":"hk","top_or_hot":-1,"title":"Nyxoah Raises $110 Million to Accelerate US Launch of Genio Sleep Apnea Device","media":"MT Newswires Live","content":"<html><body><p> Nyxoah (NYXH) secured $110 million in new capital to support the US commercial rollout of its Genio sleep apnea treatment system, the medical technology company said late Wednesday.</p><p>The company completed a $95 million equity financing and expects to receive the second $15 million tranche of its European Investment Bank loan by the end of June.</p><p>Nyxoah said the funding will help accelerate the commercialization of Genio in the US, where it has built a sales force of 40 representatives following the device's US Food and Drug Administration approval in 2025.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nyxoah Raises $110 Million to Accelerate US Launch of Genio Sleep Apnea Device</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNyxoah Raises $110 Million to Accelerate US Launch of Genio Sleep Apnea Device\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-11 04:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Nyxoah (NYXH) secured $110 million in new capital to support the US commercial rollout of its Genio sleep apnea treatment system, the medical technology company said late Wednesday.</p><p>The company completed a $95 million equity financing and expects to receive the second $15 million tranche of its European Investment Bank loan by the end of June.</p><p>Nyxoah said the funding will help accelerate the commercialization of Genio in the US, where it has built a sales force of 40 representatives following the device's US Food and Drug Administration approval in 2025.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NYXH","symbol_name":"Nyxoah SA","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2642476770","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642476770","pubTimestamp":1781124929,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Nyxoah  secured $110 million in new capital to support the US commercial rollout of its Genio sleep apnea treatment system, the medical technology company said late Wednesday.The company completed a $95 million equity financing and expects to receive the second $15 million tranche of its European Investment Bank loan by the end of June.Nyxoah said the funding will help accelerate the commercialization of Genio in the US, where it has built a sales force of 40 representatives following the device's US Food and Drug Administration approval in 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NYXH":"Nyxoah SA","AAQC":"Accelerate Acquisition Corp","BK4082":"医疗保健设备"},"translate_title":"Nyxoah融资1.1亿美元加速Genio睡眠呼吸暂停设备在美国的上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AAQC":1.5,"NYXH":1},"content_text":"Nyxoah (NYXH) secured $110 million in new capital to support the US commercial rollout of its Genio sleep apnea treatment system, the medical technology company said late Wednesday.The company completed a $95 million equity financing and expects to receive the second $15 million tranche of its European Investment Bank loan by the end of June.Nyxoah said the funding will help accelerate the commercialization of Genio in the US, where it has built a sales force of 40 representatives following the device's US Food and Drug Administration approval in 2025.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}